CEO Interview on Vox Markets

Summary by AI ^BETAClose X

MedPal AI Plc announced the publication of a feature interview with its CEO on Vox Markets, detailing the recent major upgrade to its wellness app and its strategic rollout through a partnership with Epassi UK Limited, which grants access to over 11 million employees at companies like Siemens and Volvo. The interview highlights significant AI enhancements in the app, including a new multimodal AI assistant, test result interpretation, personalized health tracking, and real-time wearable data integration, all supporting the company's automated pharmacy fulfilment platform, MedPal.clinic. This dual-engine approach aims to transform personalized preventive health, offering investors insights into MedPal AI's long-term vision.

Disclaimer*

Medpal AI PLC

09 December 2025

9 December 2025

RNS REACH

MedPal AI Plc

("MedPal AI" or the "Company")

CEO Interview Published on Vox Markets

MedPal AI plc (AIM: MPAL), the UK-based digital health and artificial intelligence company, is pleased to announce the publication of a feature interview with Chief Executive Officer Jason Drummond on Vox Markets, one of the UK's leading platforms for retail investor engagement.

In the interview, Mr. Drummond discusses the Company's recently launched major upgrade to the MedPal AI wellness app and the strategic rollout of the updated platform through its partnership with Epassi UK Limited, which provides access to more than 11 million employees across the UK, including those at Siemens and Volvo.

The discussion highlights the significant AI enhancements introduced in the latest app release, including a new multimodal AI assistant, test result upload and interpretation, longitudinal health tracking through memory-based AI personalisation, and real-time integration with wearable health data. Mr. Drummond also elaborates on how the app fits into MedPal AI's broader business model, supporting the Company's automated pharmacy fulfilment platform, MedPal.clinic.

The interview offers investors valuable insights into MedPal's long-term vision of transforming personalised preventive health through a dual-engine approach, combining engaging AI-powered wellness tools with scalable clinical service fulfilment.

The full interview can be viewed here:

https://www.voxmarkets.co.uk/articles/medpal-transforming-wellness-ai-epassi-and-the-future-of-preventive-health-804fe1f

For further information, please contact:

MedPal AI plc

Jason Drummond

www.medpalplc.com

Clear Capital Markets Limited

Bob Roberts

+44(0) 20 3869 6080

Winterflood Retail Access Platform

Sophia Bechev, Kaitlan Billings

WRAP@winterflood.com

+44(0) 20 3100 0214

About MedPal AI

MedPal AI is a UK-based digital health company focused on AI-driven wellness and personalised healthcare. Its flagship app integrates over 100 wearable devices and health apps to offer individualised lifestyle guidance via a conversational AI assistant. The Company also operates MedPal.clinic, a 24/7 automated pharmacy platform providing nationwide prescription fulfilment using advanced robotics and AI triage systems.

MedPal AI's partnership with Epassi UK enables free access to its wellness app for over 11 million employees at major corporates. The Company is also developing opportunities in B2B licensing and insurance-linked wellness programmes.

Note: This announcement is a non-regulatory RNS Reach disclosure intended to provide information to investors on media coverage and company developments that may be of interest.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END